According to the Zhitong Finance APP, SL PHARM (002038.SZ) announced that the company recently received the drug registration certificate for Telmisartan and Amlodipine Tablets (II) (brand name: Lishengyuan®) approved by the National Medical Products Administration.

It is reported that Telmisartan and Amlodipine Tablets (II) is a compound preparation consisting of Telmisartan and Amlodipine. Telmisartan is an angiotensin II receptor antagonist that lowers blood pressure by blocking the effects of angiotensin II; Amlodipine is a calcium channel blocker that primarily lowers blood pressure by inhibiting calcium ions from entering heart and smooth muscle cells. The combination of Telmisartan and Amlodipine can enhance the antihypertensive effect and reduce drug side effects. This product is suitable for primary hypertension and as a substitute treatment. Patients receiving combined treatment with Telmisartan tablets and Amlodipine tablets can switch to this product with the same component dosage, and it is also suitable for those whose single-drug antihypertensive treatment is ineffective, potentially reducing the risk of myocardial infarction and other complications